Foundation Medicine, Inc. (FMI)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Dow Dives Nearly 300 Points as Trump Ratchets Up China Trade Fight

Dow Dives Nearly 300 Points as Trump Ratchets Up China Trade Fight

U.S. stocks fall sharply on Tuesday after Donald Trump threatens to unleash a fresh round of tariffs on $200 billion worth of goods from China.

Foundation Medicine To Present At Upcoming Investor Conferences

Foundation Medicine To Present At Upcoming Investor Conferences

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Goldman Sachs Annual Healthcare Conference on Tuesday, June 12, 2018 at 1:20 p.

Foundation Medicine And Collaborators To Present New Data At ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) To Inform Personalized Approaches In Cancer Care

Foundation Medicine And Collaborators To Present New Data At ASCO 2018 Supporting Comprehensive Genomic Profiling (CGP) To Inform Personalized Approaches In Cancer Care

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated from its comprehensive genomic profiling (CGP) assays will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5, 2018 in Chicago.

Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration With Merck

Foundation Medicine Establishes Immuno-Oncology Companion Diagnostics Collaboration With Merck

Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration with Merck, known as MSD outside the United States and Canada, to develop companion diagnostic tests for use with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy and the first...

Foundation Medicine Receives New ADLT Status For FoundationOne CDx™ From The Centers For Medicare And Medicaid Services (CMS)

Foundation Medicine Receives New ADLT Status For FoundationOne CDx™ From The Centers For Medicare And Medicaid Services (CMS)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that under the Protecting Access to Medicare Act of 2014 (PAMA) the Centers for Medicare & Medicaid Services (CMS) approved new Advanced Diagnostic Laboratory Test (ADLT) status for FoundationOne CDx™.

Foundation Medicine Announces 2018 First Quarter Results And Recent Highlights

Foundation Medicine Announces 2018 First Quarter Results And Recent Highlights

Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018.

Foundation Medicine Launches Gene Expression Profiling Program To Identify Known And Novel Biomarkers In Advanced Cancer

Foundation Medicine Launches Gene Expression Profiling Program To Identify Known And Novel Biomarkers In Advanced Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development.

Foundation Medicine, Roche And DIAN Diagnostics Collaborate To Advance Personalized Cancer Care In China

Foundation Medicine, Roche And DIAN Diagnostics Collaborate To Advance Personalized Cancer Care In China

Foundation Medicine, Inc., (NASDAQ:FMI), F.

Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. Food And Drug Administration

Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. Food And Drug Administration

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.

Foundation Medicine Announces Final National Coverage Determination (NCD) From The Centers For Medicare & Medicaid Services (CMS), Including Coverage For FoundationOne CDx™ Across All Solid Tumors

Foundation Medicine Announces Final National Coverage Determination (NCD) From The Centers For Medicare & Medicaid Services (CMS), Including Coverage For FoundationOne CDx™ Across All Solid Tumors

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who receive next generation sequencing...

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co.

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc.

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company's 38 th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017.

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine, Inc. (NASDAQ:FMI) and the European Organisation for Research and Treatment of Cancer (EORTC) announced today a collaboration in which Foundation Medicine's comprehensive genomic profiling (CGP)...

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company has entered into a broad partnership with Pfizer Inc.

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $48.

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne ® Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be...

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2017.

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung...

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017.

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom Civik to the role of chief commercial officer.

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it received approval from the New York State (NYS) Clinical Laboratory Evaluation Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA...